TASSINARI, ELISA
 Distribuzione geografica
Continente #
AS - Asia 1.571
EU - Europa 494
NA - Nord America 466
SA - Sud America 103
AF - Africa 61
Totale 2.695
Nazione #
SG - Singapore 563
CN - Cina 531
US - Stati Uniti d'America 453
IT - Italia 196
KR - Corea 155
HK - Hong Kong 127
VN - Vietnam 105
NL - Olanda 96
BR - Brasile 72
IN - India 43
CI - Costa d'Avorio 32
DE - Germania 31
FI - Finlandia 23
SC - Seychelles 23
FR - Francia 19
CH - Svizzera 18
SE - Svezia 18
RU - Federazione Russa 17
IE - Irlanda 16
AT - Austria 15
JP - Giappone 15
AR - Argentina 13
GB - Regno Unito 12
JO - Giordania 12
BG - Bulgaria 11
CA - Canada 8
PL - Polonia 8
CL - Cile 7
ID - Indonesia 6
LT - Lituania 5
EC - Ecuador 4
BD - Bangladesh 3
ES - Italia 3
PK - Pakistan 3
ZA - Sudafrica 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
CO - Colombia 2
MX - Messico 2
TR - Turchia 2
UY - Uruguay 2
VE - Venezuela 2
DO - Repubblica Dominicana 1
EE - Estonia 1
ET - Etiopia 1
HN - Honduras 1
IL - Israele 1
IR - Iran 1
KG - Kirghizistan 1
KZ - Kazakistan 1
MA - Marocco 1
ML - Mali 1
NI - Nicaragua 1
PT - Portogallo 1
PY - Paraguay 1
RS - Serbia 1
UA - Ucraina 1
Totale 2.695
Città #
Singapore 417
Hefei 282
Seoul 154
Ashburn 135
Hong Kong 124
Santa Clara 52
Bologna 48
Beijing 40
Abidjan 32
Boardman 31
Hanoi 29
Bengaluru 26
Ho Chi Minh City 26
Dallas 21
Milan 20
Castel Maggiore 17
Redondo Beach 17
Dublin 16
Guangzhou 16
Los Angeles 16
Helsinki 15
Tokyo 15
Amman 12
Bern 12
Sofia 11
Vienna 11
Rome 10
Tongling 10
Falkenstein 9
Hyderabad 9
New York 9
Amsterdam 8
Buffalo 8
Munich 8
Nuremberg 8
Biên Hòa 7
Turin 7
Lappeenranta 6
São Paulo 6
Warsaw 6
Jakarta 5
Bari 4
Boston 4
Da Nang 4
Frankfurt am Main 4
Haiphong 4
Montreal 4
Moscow 4
Rimini 4
Zhengzhou 4
Belo Horizonte 3
Chennai 3
Chicago 3
Columbus 3
Enschede 3
Houston 3
Nanjing 3
Paris 3
Ravenna 3
Rio de Janeiro 3
San Francisco 3
Shanghai 3
Telgate 3
Tianjin 3
Trieste 3
Venice 3
Zurich 3
Adana 2
Atlanta 2
Avellaneda 2
Bollate 2
Brooklyn 2
Bắc Ninh 2
Cagliari 2
Changsha 2
Chengdu 2
Elk Grove Village 2
Florence 2
Gatineau 2
Genoa 2
Gujrat 2
Johannesburg 2
Legnano 2
London 2
Maipú 2
Mantova 2
Mexico City 2
Modena 2
Montevideo 2
Mumbai 2
Ninh Bình 2
Nova Iguaçu 2
Orem 2
Perugia 2
Petrópolis 2
Phú Thọ 2
Quảng Ngãi 2
Quận Bình Thạnh 2
Quận Một 2
Rancho Palos Verdes 2
Totale 1.864
Nome #
The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy 186
Insights into the impact of chromosome 3p mutations in advanced renal cell carcinoma treated with immune-based combinations or targeted therapy: A single-center experience 142
Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw 128
A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy 128
A prospective study on the early evaluation of response to androgen receptor-targeted agents with 11C-Choline, 68Ga-PSMA, and 18F-FACBC PET in metastatic castration-resistant prostate cancer: a single-center experience 127
Metabolic pseudoprogression in a patient with metastatic KIT exon 11 GIST after 1 month of first-line imatinib: a case report 125
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study 124
Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis 124
Tumor growth rate to assess therapy response to immune-based combinations for metastatic renal cell carcinoma 124
The value of molecular features in predicting efficacy of immuno-combinations in kidney cancer: just a drop in the ocean? 123
Dual-energy spectral CT in renal cell carcinoma: dawn of a brand-new era? 120
Appropriateness of Mini-Invasive Approaches for Nausea and Vomiting Refractory to Medical Therapy in Palliative Care Setting: A Case Report 112
Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis 111
State of the art of adjuvant immunotherapy in urothelial cancer: New developments and upcoming changes 107
Novel Immune Checkpoint Inhibitor Targets in Advanced or Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives 101
Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis 87
An update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma 80
Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers 64
The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study 64
Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study 57
How Do Molecular Classifications Affect the Neoadjuvant Treatment of Muscle-Invasive Urothelial Carcinoma? 55
Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy 55
TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab 51
Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis 51
Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer 50
What is the risk of hepatotoxicity induced by immune-checkpoint inhibitors and how can we avoid it? 48
Do we need alternative PD-1 inhibitors for the treatment of renal cell carcinoma? 45
Current androgen receptor antagonists under investigation for resistant prostate cancer: progress and challenges 44
Prostate cancer and novel pharmacological treatment options - what's new for 2022? 36
The Prognostic Role of 68GA-PSMA-PET/CT in Metastatic Hormone-Sensitive Prostate Cancer: A Preliminary Analysis 36
Re: Atezolizumab Plus Cabozantinib Versus Cabozantinib Monotherapy for Patients with Renal Cell Carcinoma After Progression with Previous Immune Checkpoint Inhibitor Treatment (CONTACT-03): A Multicentre, Randomised, Open-label, Phase 3 Trial 28
Immune-based Combinations in Intermediate-/Poor-risk Patients with Non-clear Cell Renal Cell Carcinoma: Results from the ARON-1 Study 17
Pathological and Clinical Implications of Tumor Microenvironment Evaluated With Multiplex Immunohistochemistry in Testicular Embryonal Carcinoma 14
Totale 2.764
Categoria #
all - tutte 7.511
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.511


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/2023137 0 0 0 0 14 3 8 5 39 11 25 32
2023/2024155 10 18 13 8 14 29 4 15 11 5 18 10
2024/20251.026 44 85 60 49 80 42 52 43 17 97 198 259
2025/20261.446 303 368 264 244 246 21 0 0 0 0 0 0
Totale 2.764